Mirum rises on FDA nod for rare bone disorder drug 

By Reuters News

** Shares of drugmaker Mirum Pharmaceuticals MIRM.O rise 2.8% to $92.25 premarket

** The US FDA late on Friday approved MIRM's drug Atebrioz to treat a rare bone disorder known as fibrodysplasia ossificans progressiva (FOP)

** The approval is based off a 63-patient study, in which Atebrioz significantly cut new bone formation compared to placebo at week 24

** FOP causes muscles, tendons and ligaments to gradually transform into bone, restricting movement and leading to severe disability

** MIRM expects to launch the drug in October

** Mirum had licensed the drug from Incyte INCY.O earlier this year for $16 million upfront, along with potential milestone payments and sales royalties

** As of last close, MIRM stock was up 13.56% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.